| Literature DB >> 33741694 |
Fazlur Rahman Talukdar1, Sheila C Soares Lima2, Rita Khoueiry3, Ruhina Shirin Laskar3, Cyrille Cuenin3, Bruna Pereira Sorroche3,4, Anne-Claire Boisson3, Behnoush Abedi-Ardekani3, Christine Carreira3, Diana Menya5, Charles P Dzamalala6, Mathewos Assefa7, Abraham Aseffa8, Vera Miranda-Gonçalves9, Carmen Jerónimo9, Rui M Henrique9, Ramin Shakeri10, Reza Malekzadeh10, Nagla Gasmelseed11, Mona Ellaithi12, Nitin Gangane13, Daniel R S Middleton3, Florence Le Calvez-Kelm3, Akram Ghantous3, Maria Leon Roux3, Joachim Schüz3, Valerie McCormack3, M Iqbal Parker14, Luis Felipe Ribeiro Pinto2, Zdenko Herceg1.
Abstract
Epigenetic mechanisms such as aberrant DNA methylation (DNAme) are known to drive esophageal squamous cell carcinoma (ESCC), yet they remain poorly understood. Here, we studied tumor-specific DNAme in ESCC cases from nine high-incidence countries of Africa, Asia, and South America. Infinium MethylationEPIC array was performed on 108 tumors and 51 normal tissues adjacent to the tumors (NAT) in the discovery phase, and targeted pyrosequencing was performed on 132 tumors and 36 NAT in the replication phase. Top genes for replication were prioritized by weighting methylation results using RNA-sequencing data from The Cancer Genome Atlas and GTEx and validated by qPCR. Methylome analysis comparing tumor and NAT identified 6,796 differentially methylated positions (DMP) and 866 differential methylated regions (DMR), with a 30% methylation (Δβ) difference. The majority of identified DMPs and DMRs were hypermethylated in tumors, particularly in promoters and gene-body regions of genes involved in transcription activation. The top three prioritized genes for replication, PAX9, SIM2, and THSD4, had similar methylation differences in the discovery and replication sets. These genes were exclusively expressed in normal esophageal tissues in GTEx and downregulated in tumors. The specificity and sensitivity of these DNAme events in discriminating tumors from NAT were assessed. Our study identified novel, robust, and crucial tumor-specific DNAme events in ESCC tumors across several high-incidence populations of the world. Methylome changes identified in this study may serve as potential targets for biomarker discovery and warrant further functional characterization. SIGNIFICANCE: This largest genome-wide DNA methylation study on ESCC from high-incidence populations of the world identifies functionally relevant and robust DNAme events that could serve as potential tumor-specific markers. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/10/2612/F1.large.jpg. ©2021 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33741694 DOI: 10.1158/0008-5472.CAN-20-3445
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701